Search Within

Mario E Lacouture

Formats
  1. Journal Article (220)
  2. Meeting Abstract (171)
  3. Book Section (25)
  4. Review (18)
  5. Research Letter (9)
  6. Guidelines (5)
  7. Book Whole (2)
  8. Conference Paper (2)
  9. Editorial (2)
  10. Miscellaneous (2)
  11. Correspondence (1)
Groups
  1. Department of Medicine (457)
  2. Dermatology (457)
  3. Dermatology Service (457)
  4. Division of Subspecialty Medicine (457)
  5. Survivorship Research (457)
  6. Solid Tumor Oncology Division (142)

More Groups

People
  1. Viswanath Reddy Belum (37)
  2. Shari Goldfarb (34)
  3. Alina Markova (31)
  4. Azael Freites Martinez (27)
  5. Yevgeniy Balagula (26)
  6. Stephen Dusza (25)

More People

Years
  1. 2025 (4)
  2. 2024 (17)
  3. 2023 (24)
  4. 2022 (31)
  5. 2021 (32)
  6. 2020 (27)

More Years

Publications
  1. Journal of Clinical Oncology (90)
  2. Journal of the American Academy of Dermatology (51)
  3. Annals of Oncology (20)
  4. Supportive Care in Cancer (17)
  5. The Oncologist (16)
  6. Blood (12)

More Publications

Publishers
  1. American Society of Clinical Oncology (92)
  2. Mosby Elsevier (55)
  3. Oxford University Press (44)
  4. Elsevier Inc. (35)
  5. Springer (34)
  6. Wiley Blackwell (29)

More Publishers

Results (457)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Dermatological adverse events in prostate cancer patients treated with the androgen receptor inhibitor apalutamide
    Journal Article

    Pan, A.; Reingold, R. E.; Zhao, J. L.; Moy, A.; Kraehenbuehl, L.; Dranitsaris, G.; McBride, S. M.; Scher, H. I.; Kollmeier, M. A.; Xiao, H.; more...
    Journal of Urology (2022)

    Fulltext@MSK | Save
  • Management of dermatologic events associated with the Nectin-4-directed antibody-drug conjugate enfortumab vedotin
    Journal Article

    Lacouture, M. E.; Patel, A. B.; Rosenberg, J. E.; O'Donnell, P. H.
    The Oncologist (2022)

    Fulltext@MSK | Save
  • European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force ‘Dermatology for cancer patients’ position statement
    Guidelines

    Apalla, Z.; Nikolaou, V.; Fattore, D.; Fabbrocini, G.; Freites-Martinez, A.; Sollena, P.; Lacouture, M.; Kraehenbuehl, L.; Stratigos, A.; Peris, K.; more...
    Journal of the European Academy of Dermatology and Venereology (2022)

    Fulltext@MSK | Save
  • Dermatologic events associated with the anti-CCR4 antibody mogamulizumab: Characterization and management
    Review

    Musiek, A. C. M.; Rieger, K. E.; Bagot, M.; Choi, J. N.; Fisher, D. C.; Guitart, J.; Haun, P. L.; Horwitz, S. M.; Huen, A. O. L.; Kwong, B. Y.; more...
    Dermatology and Therapy (2022)

    Fulltext@MSK | Save
  • Real-world assessment and treatment of locally advanced basal cell carcinoma: Findings from the RegiSONIC disease registry
    Journal Article

    Sekulic, A.; Yoo, S.; Kudchadkar, R.; Guillen, J.; Rogers, G.; Chang, A. L. S.; Guenthner, S.; Raskin, B.; Dawson, K.; Mun, Y.; more...
    PLoS ONE (2022)

    Fulltext@MSK | Save
  • A multidisciplinary approach to optimizing care of patients treated with alpelisib
    Journal Article

    Rugo, H. S.; Lacouture, M. E.; Goncalves, M. D.; Masharani, U.; Aapro, M. S.; O'Shaughnessy, J. A.
    Breast (2022)

    Fulltext@MSK | Save
  • Interim results of a pilot, prospective, randomized, double-blinded, vehicle- and comparator-controlled trial on safety and efficacy of a topical inhibitor of janus kinase 1/2 (ruxolitinib INCB018424 phosphate 1.5% cream) for non- sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease
    Meeting Abstract

    Markova, A.; Pan, A.; Dusza, S.; Chowdhury, A.; Kukoyi, O.; Perales, M. A.; Lacouture, M.; Prockop, S.; Ponce, D. M.
    Blood (2021)

    Fulltext@MSK | Save
  • Safety profile of ripretinib, including impact of alopecia, and Palmar-Plantar Erythrodysesthesia Syndrome (PPES) on patient-reported outcomes (PROs), in ≥ fourth-line advanced gastrointestinal stromal tumors (GIST): Analyses from INVICTUS
    Meeting Abstract

    Reichardt, P.; Heinrich, M.; George, S.; Zalcberg, J. R.; Bauer, S.; Gelderblom, H.; Schöffski, P.; Serrano, C.; Jones, R. L.; Attia, S.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • A phase II study to evaluate the safety and efficacy of OQL011 on VEGFR inhibitor-associated hand-foot-skin reaction in cancer patients
    Meeting Abstract

    Lacouture, M. E.; Anadkat, M. J.; Marathe, O. S.; Vogelzang, N. J.; Lam, E. T.; Kaffenberger, B.; Choi, J. N.; Webb, M. L.; Tyler, R. C.; Ju, J. G.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Comparison of checkpoint inhibitor treatment-related cutaneous adverse events in racial and ethnic minority and Caucasian cohorts at Memorial Sloan Kettering Cancer Center
    Meeting Abstract

    Geisler, A.; Barrios, D. M.; Phillips, G.; Nouvini, R.; Lacouture, M. E.; Noor, S.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save